Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2018

01-08-2018 | Bone and Soft Tissue Sarcomas

Strategic Delay: Histology- and Biology-Driven Decision-Making in Recurrent Retroperitoneal Sarcoma

Author: Carol J. Swallow, MD, PhD, FRCS(C), FACS

Published in: Annals of Surgical Oncology | Issue 8/2018

Login to get access

Excerpt

In this issue, the sarcoma group at the MD Anderson Cancer Center (MDACC) has tackled the important and challenging problem of well-differentiated liposarcoma (WD-LPS) of the retroperitoneum, as part of a series of recent contributions that explore approaches to retroperitoneal sarcoma (RPS) and outcomes at their institution.1 In particular, Ikoma et al. report the survival and re-recurrence rates after resection of recurrent WD-LPS of the retroperitoneum. Their results are a stark reminder of the serious impact that the diagnosis of primary RP WD-LPS has on patients’ expectations for life and of the gravity of recurrence. …
Literature
1.
2.
Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238:358–71.PubMedPubMedCentral
3.
Gronchi A, Strauss DC, Miceli R, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016;263:1002–9.CrossRefPubMed
4.
Hamilton TD, Cannell AJ, Kim M, et al. Results of resection for recurrent or residual retroperitoneal sarcoma after failed primary treatment. Ann Surg Oncol. 2017;24:211–8.CrossRefPubMed
5.
Gronchi A, Miceli R, Allard MA, et al. Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection. Ann Surg Oncol. 2015;22:1447–54.CrossRefPubMed
6.
Anaya DA, Lahat G, Liu J, et al. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg. 2009;249:137–42.CrossRefPubMed
7.
Park JO, Qin LX, Prete FP, et al. Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule. Ann Surg. 2009;250:977–82.CrossRefPubMedPubMedCentral
8.
MacNeill AJ, Miceli R, Strauss DC, et al. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group. Cancer. 2017;123:1971–8.CrossRefPubMed
9.
Italiano A, Toulmonde M, Cioffi A, et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol. 2012;23:1601–7.CrossRefPubMed
10.
Jones RL, Fisher C, Al-Muderis O, Judson IR, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41:2853–60.CrossRefPubMed
Metadata
Title
Strategic Delay: Histology- and Biology-Driven Decision-Making in Recurrent Retroperitoneal Sarcoma
Author
Carol J. Swallow, MD, PhD, FRCS(C), FACS
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6472-z

Other articles of this Issue 8/2018

Annals of Surgical Oncology 8/2018 Go to the issue

GASTROINTESTINAL ONCOLOGY

Development and External Validation of a Simplified Nomogram Predicting Individual Survival After R0 Resection for Gastric Cancer: An International, Multicenter Study

Urologic Oncology

Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette–Guérin Therapy

Colorectal Cancer

Management of Mucinous Appendiceal Tumors

Gastrointestinal Oncology

Techniques for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Bone and Soft Tissue Sarcomas

Long-Term Outcome After Surgery for a Localized Retroperitoneal Soft Tissue Sarcoma in Elderly Patients: Results from a Retrospective, Single-Center Study

Breast Oncology

Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States